Bell Potter analyst John Hester maintained a Buy rating on Paradigm Biopharmaceuticals Ltd. (PBIGF – Research Report) today and set a price target of A$2.20. The company’s shares closed last Thursday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback